Mikov, Momir
Results 1-12 of 12 (Search time: 0.004 seconds).
Issue Date | Title | Author(s) | |
---|---|---|---|
1 | 1-Jan-2015 | An advanced microencapsulated system: A platform for optimized oral delivery of antidiabetic drug-bile acid formulations | Mooranian A.; Negrulj R.; Mathavan S.; Martinez J.; Sciarretta J.; Chen-Tan N.; Mukkur T.; Momir Mikov ; Mladena Lalić-Popović ; Maja Stojančević; Svetlana Goločorbin-Kon ; Al-Salami H. |
2 | 1-Jan-2019 | Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids | Mathavan S.; Ionescu C.; Božica Kovačević; Momir Mikov ; Svetlana Goločorbin-Kon ; Mooranian A.; Dass C.; Al-Salami H. |
3 | 9-Sep-2014 | Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol | Mooranian A.; Negrulj R.; Chen-Tan N.; Al-Sallami H.; Fang Z.; Mukkur T.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Watts G.; Matthews V.; Arfuso F.; Al-Salami H. |
4 | 28-Jul-2014 | Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A characterization study | Mooranian A.; Negrulj R.; Chen-Tan N.; Al-Sallami H.; Fang Z.; Mukkur T.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Arfuso F.; Al-Salami H. |
5 | 1-Jan-2015 | Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study | Mooranian A.; Negrulj R.; Momir Mikov ; Svetlana Goločorbin-Kon ; Arfuso F.; Al-Salami H. |
6 | 12-Nov-2018 | Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes | Mooranian A.; Zamani N.; Takechi R.; Al-Sallami H.; Momir Mikov ; Svetlana Goločorbin-Kon ; Božica Kovačević; Arfuso F.; Al-Salami H. |
7 | 1-Jan-2014 | Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes | Mooranian A.; Negrulj R.; Al-Sallami H.; Fang Z.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Watts G.; Matthews V.; Arfuso F.; Lambros A.; Al-Salami H. |
8 | 1-Jan-2019 | Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice | Mooranian A.; Zamani N.; Takechi R.; Al-Sallami H.; Momir Mikov ; Svetlana Goločorbin-Kon ; Božica Kovačević; Arfuso F.; Al-Salami H. |
9 | 1-Jan-2015 | Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment | Mooranian A.; Negrulj R.; Al-Sallami H.; Fang Z.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Aruso F.; Al-Salami H. |
10 | 1-Feb-2019 | Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment | Mooranian A.; Zamani N.; Momir Mikov ; Svetlana Goločorbin-Kon ; Goran Stojanović ; Arfuso F.; Al-Salami H. |
11 | 1-Jan-2014 | Stability and release kinetics of an advanced gliclazide-cholic acid formulation: The Use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics | Mooranian A.; Negrulj R.; Mathavan S.; Martinez J.; Sciarretta J.; Chen-Tan N.; Mukkur T.; Momir Mikov ; Mladena Lalić-Popović ; Maja Stojancěvić; Svetlana Goločorbin-Kon ; Al-Salami H. |
12 | 3-Jul-2016 | Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes | Negrulj R.; Mooranian A.; Chen-Tan N.; Al-Sallami H.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Watts G.; Arfuso F.; Al-Salami H. |